ライフサイエンスコーパス: galectin 3

1 erminal pro-B-type natriuretic peptide], and galectin-3).

2 functional beta-galactoside-binding protein, galectin-3.

3 homonas depleted the extracellular levels of galectin-3.

4 s against FcepsilonRI, FcepsilonRII/CD23 and galectin-3.

5 liver production of the profibrotic lectin, galectin-3.

6 factor, transforming growth factor beta, and galectin-3.

7 ntly after preloading with exogenously added galectin-3.

8 phosphorylation beyond the known example of galectin-3.

9 iguration for discovery of new inhibitors of galectin-3.

10 ed higher levels of extracellular release of galectin-3.

11 s type 1 (HSV-1), but not HSV-2, binds human galectin-3.

12 tor, as well as profibrotic proteins such as galectin-3.

13 ors become upregulated, including the lectin galectin-3.

14 thelial cell surfaces treated with exogenous galectin-3.

15 in fibrotic areas contained large amounts of galectin-3.

16 NKp30 blocking Ab and an inhibitory ligand, galectin-3.

17 luble form of ST2 (33 [24.6-48.1] ng/mL) and galectin 3 (17.8 [14.1-22.8] ng/mL) were higher, and for

18 Colocalization of alphaS pathology with galectin-3 (a marker of endo-lysosomal membrane rupture)

19 We hypothesized that human galectin-3, a beta-galactoside-binding lectin involved i

20 f more highly sulfated C4S, which binds less galectin-3, a beta-galactoside-binding protein.

21 Galectin-3, a carbohydrate-binding protein with affinity

22 Galectin-3, a profibrotic mediator, is linked to the dev

23 nal analyses, circulating baseline levels of galectin-3, a protein involved in myocardial fibrosis an

24 the staphylococcal protease SspB inactivates galectin-3, abrogating its stimulation of oxygen radical

25 ted with rapid decline in eGFR (per 1-SD log-galectin-3; adjusted odds ratio [OR], 1.49; 95% confiden

26 te the biological counterreceptor MUC16 from galectin-3 affinity columns, suggesting that association

27 Using two different galectin-3 affinity purification processes, we extracted

28 Further, galectin-3 alone was able to initiate neutrophil migrati

29 Inhibition of galectin-3 also attenuated the progression of cardiac re

30 ILK, Src, and galectin-3 also mediate EGF stimulation of caveolin-1 ph

31 lso observed colocalization between YopD and Galectin-3, an indicator of endosomal membrane damage.

32 onic anhydrase-12, and NC markers brachyury, galectin-3 and CD24 in cells of the NP irrespective of a

33 Galectin-3 and galectin-1, binding partners of LGALS3BP,

34 relevance, human adhesion/growth-regulatory galectin-3 and galectin-4.

35 in promoting MUC16's binding affinity toward galectin-3 and in causing retention of the lectin on the

36 The relative expression of galectin-3 and matrix metalloproteinase 9 (MMP9) was eva

37 We show that EGF signaling to RhoA is galectin-3 and phospho-caveolin-1 dependent and promotes

38 Thus, we studied the role of galectin-3 and platelet collagen receptors in platelet-i

39 The impact of galectin-3 and protease expression on S. aureus virulenc

40 us approximately 10S particle that contained galectin-3 and U1 snRNP and this particle was sufficient

41 Circulating galectin-3 and various extracellular matrix biomarkers w

42 (the human adhesion/growth-regulatory lectin galectin-3) and its consequences in structural terms wer

43 5 (growth differentiation factor 15), GAL-3 (galectin-3), and Cys-C (cystatin-C) were assessed before

44 ammation and caused up-regulation of Cxcl16, Galectin-3, and Nedd9, among others.

45 brogated by bacterium-derived proteolysis of galectin-3, and SspB was identified as the major proteas

46 overall showed smaller lesion sizes than the galectin-3(+/+) animals.

47 nti-fibronectin antibody and beta-lactose, a galectin-3 antagonist, significantly blocked DC exosome-

48 ions 3-5) of the glycerol gradient with anti-galectin-3 antibodies.

49 egative form of galectin-3, Gal-3C, and anti-galectin-3 antibody M3/38) or collagen receptor-mediated

50 In conclusion, elevated levels of plasma galectin-3 are associated with increased risks of rapid

51 C50 values for known carbohydrate ligands of galectin-3 are in good agreement with the Kd values repo

52 omatography based on their binding or not to galectin-3, are targeted to kinetically different endocy

53 The role of galectin-3 as a modulator of inflammation has been studi

54 These findings suggest LGALS3BP and galectin-3 as new targets to treat metastatic cancer and

55 In addition, the assay format for the galectin-3/ASF pair could be easily applied in screening

56 the self-association-related multivalency of galectin-3 at the residue-specific level.

57 In REN2 rats, pharmacological inhibition of galectin-3 attenuated LV dysfunction and fibrosis.

58 disruption and pharmacological inhibition of galectin-3 attenuates cardiac fibrosis, LV dysfunction,

59 rn blot, an intact ( approximately 28.0 kDa) galectin-3 band was identified in tear samples from heal

60 Galectin-3 binding protein (Gal-3BP) is a large hypergly

61 Purification indicated that Galectin-3 binding protein (LGALS3BP) is the active fact

62 In murine mammary epithelial cancer cells, galectin-3 binding to beta1,6-acetylglucosaminyltransfer

63 CD146 was the major galectin-3-binding ligand and strongly co-localized with

64 Thus, CD146/MCAM is the functional galectin-3-binding ligand on endothelial cell surfaces r

65 Here we sought to identify the galectin-3-binding molecule(s) on the endothelial cell s

66 Galectin-3-binding protein (gal3bp) and its receptor/lig

67 roteinase 9, S100A8/S100A9, cathepsin D, and galectin-3-binding protein) improved risk prediction and

68 00A8), S100A9, cathepsin B, fibronectin, and galectin-3-binding protein.

69 Relationships among galectin-3, biomarkers, and LV remodeling were analyzed

70 Moreover, galectin-3 bound to N-linked glycans on CD146 and induce

71 Moreover, the galectin-3-bound glycoform increased in cancer, suggesti

72 chomonas CPI-GC that had reduced affinity to galectin-3 but maintained affinity to galectin-1 suppres

73 endocytic pathways in HFL-1 cells expressing galectin-3 but not in SKBR3 cells lacking galectin-3; th

74 uctures; the MDA-MB-231 cells had no surface galectin-3 but used surface galectin-1 for interaction w

75 However, galectin-3, but not galectin-1, was expressed in the DCT

76 with the Kd values reported and measured for galectin-3 by isothermal titration calorimetry (ITC).

77 lectin-3 inhibition, showed no inhibition of galectin-3 by the polysaccharides.

78 suggest that once extracellularly released, galectin-3 can act as a damage-associated molecular patt

79 d phase separation, and we demonstrated that galectin-3 can also undergo liquid-liquid phase separati

80 We report that galectin-3 can bind to TLR-4, and that administration of

81 Uric acid, C-reactive protein, galectin-3, carboxy-terminal telopeptide of collagen typ

82 This correspondence is a reply to Galectin-3, Cardiac Function, and Fibrosis by Wouter C.

83 ectin-3 levels over time, from a low to high galectin-3 category, were associated with significantly

84 activating polypeptide II, ectodysplasin A2, Galectin-3, chemokine (C-X-C motif) ligand 2, Nidogen1,

85 In addition, galectin-3 colocalized predominantly with the HPS-5 comp

86 In the cell body, galectin-3 colocalizes with melanosome-destined cargo, s

87 Galectin-3 concentration was significantly associated wi

88 Per SD increase in log-transformed galectin-3 concentration, the risks of all-cause mortali

89 We measured galectin-3 concentrations in baseline samples from the G

90 In conclusion, galectin-3 concentrations increased with progressive ren

91 Mean+/-SD galectin-3 concentrations were 12.8+/-4.0 ng/ml (eGFR>/=

92 We correlated galectin-3 concentrations with demographic, clinical, an

93 Galectin-3 content in tears was analyzed by quantitative

94 nt interactions of transmembrane mucins with galectin-3 contribute to maintenance of the epithelial b

95 Galectin-3 correlated significantly with certain biomark

96 Galectin-3 correlated significantly with matrix metallop

97 istration of a neutralizing antibody against galectin-3 decreases the expression of IL-1beta, IL-6, T

98 anti-inflammatory properties by assembling a galectin-3-Dectin-1-FcgammaRIIB receptor complex that ac

99 uoles or YCVs is substantially diminished in Galectin-3-deficient cells.

100 of the impaired immune response observed in galectin-3-deficient mice in vivo.

101 ce of proteases other than MMPs in promoting galectin-3 degradation in dry eye.

102 ns and clinical isolates of S. aureus caused galectin-3 degradation.

103 Similarly, caveolin-1/galectin-3-dependent EGF signaling induces motility, per

104 Molecular mechanisms underlying galectin-3-dependent inflammatory responses were further

105 cretion systems into PV membranes stimulates Galectin-3-dependent recruitment of antimicrobial GBPs t

106 Baseline galectin-3 did not correlate with any LV parameters at b

107 Furthermore, galectin-3 diminished monocyte to dendritic cell differe

108 tic liver injury, we generated dnTGF-betaRII/galectin-3(-/-) (dn/Gal3(-/-)) mice, which showed impair

109 Taking all together, galectin-3 emerges as a clinically relevant target for T

110 This suggests that in response to EGF, galectin-3 enables outside-in integrin signaling stimula

111 Galectin-3 enhanced monocyte interleukin 10 production t

112 artilage surface, and addition of multimeric galectin-3 enhances cartilage lubrication.

113 Alterations of galectin-3 expression are often seen in cancers and may

114 tion of galectin-3 protein in tears, but not galectin-3 expression in conjunctival epithelium, was si

115 ied in human infectious disease, we examined galectin-3 expression in mycobacterial infection by stud

116 studies concerning clinical implications of galectin-3 expression in patients with acute myeloid leu

117 We found that galectin-3 expression mimicked the defective expression

118 use model of transverse aortic constriction, galectin-3 expression was markedly up-regulated in the p

119 leomorphism, fibrous septation and increased galectin-3 expression, consistent with atypical parathyr

120 MP)-1 and -2 and also increased collagen and galectin-3 expression.

121 tion to isolated hepatic macrophages reduced galectin-3 expression.

122 vity troponin I (hsTnI), soluble (s)ST2, and galectin-3 from baseline to 26, 52, and 104 weeks.

123 ed with the ability of active MMP9 to cleave galectin-3 from recombinant origin.

124 Inhibitors of galectin-3 function (beta-lactose, a dominant-negative f

125 Galectin-3 (Gal-3) can cross-link surface glycoproteins

126 ing were used to investigate the function of galectin-3 (Gal-3) during the process of leukocyte recru

127 Galectin-3 (Gal-3) has been linked to cardiac remodeling

128 Galectin-3 (Gal-3) is a carbohydrate binding lectin, wit

129 Mammalian beta-galactoside-binding protein Galectin-3 (Gal-3) modulates the host innate and adaptiv

130 ST2 and galectin-3 (Gal-3) were compared head-to-head for long-t

131 We show that ablation of galectin-3 (Gal-3), a galactoside-binding lectin, accele

132 nflammation markers soluble (s)CD163, sCD14, galectin-3 (Gal-3), and Gal-3 binding protein (Gal-3BP)

133 n (beta-lactose, a dominant-negative form of galectin-3, Gal-3C, and anti-galectin-3 antibody M3/38)

134 hree different endocytic ligands-folic acid, galectin-3 (Gal3) and the Shiga toxin B-subunit (STxB).

135 We studied the role of galectin-3 (Gal3) in gastric infection by Helicobacter p

136 Galectin-3 (gal3) is known for its immunoregulatory func

137 Galectin-3 (Gal3), a lectin mainly secreted by macrophag

138 Galectin-3 (Gal3), a pleiotropic lectin, is produced by

139 ng protein (gal3bp) and its receptor/ligand, galectin-3 (gal3), are secreted proteins that initiate s

140 In further studies, we focused on galectin-3 (Gal3), identified in this study as a negativ

141 ial cells identified a lectin referred to as galectin-3 (Gal3).

142 show that a beta-galactoside-binding lectin [galectin-3 (gal3)] that recognizes the Thomsen-Friedenre

143 tandem repeats (VNTRs) that bind the lectin galectin-3; galectin-3 siRNA but not galectin-1 siRNA pr

144 bitor, which strongly suggests that blocking galectin-3 glycan recognition is an important antifibrot

145 33 ng/mL soluble form of ST2 and <17.8 ng/mL galectin 3) had reduction in left atrial volume, those a

146 Galectin-3 has an intrinsically disordered N-terminal do

147 Galectin-3 has been implicated in a broad range of biolo

148 Galectin-3 has been implicated in the development of org

149 Galectin-3 has been linked to incident renal disease, ex

150 We also find that galectin-3 has low affinity for the surface layer of ost

151 Mice deficient for galectin-3 have elevated blood parasitemia levels and im

152 and clinical use of repeated measurements of galectin-3 have not yet been reported.

153 ect activation of integrin with Mn2+ induces galectin-3, ILK, and Src-dependent RhoA activation and c

154 In contrast, parallel anti-galectin-3 immunoprecipitation of free galectin-3 molecu

155 ain of L. major, LV39, was infected, lack of galectin-3 impaired neutrophil recruitment in the footpa

156 One specific TRIM, TRIM16, interacted with Galectin-3 in a ULK1-dependent manner.

157 We investigated the potential function of galectin-3 in cell-mediated immunity using peripheral bl

158 Knockdown of galectin-3 in human corneal keratinocytes by small inter

159 Downregulation of galectin-3 in human melanocytes using short hairpin RNA

160 e show a large increase in the expression of galectin-3 in microglia and also an increase in the rele

161 In this study, we investigated the role of galectin-3 in neutrophil migration and the biological si

162 We investigated the role of galectin-3 in systemic and local responses in a murine m

163 The cooperation between TRIM16 and Galectin-3 in targeting and activation of selective auto

164 Interestingly, cleavage of endogenous galectin-3 in tear samples was impaired using a broad-sp

165 esis, cultured fibroblasts were treated with galectin-3 in the absence or presence of galectin-3 inhi

166 and also an increase in the released form of galectin-3 in the cerebrospinal fluid (CSF) 24 h after h

167 mes detected the presence of fibronectin and galectin-3 in those derived from DCs, whereas T-cell exo

168 the expression of LGALS3, the gene encoding galectin-3, in the bone marrow (BM) mononuclear cells fr

169 Nuclear galectin-3 increased and mediated increased binding of S

170 In addition, patients whose galectin-3 increased by >15% between measurements had a

171 ates but not in Staphylococcus saprophyticus Galectin-3-induced activation of the neutrophil NADPH ox

172 of CD146 expression completely abolished the galectin-3-induced secretion of IL-6 and G-CSF cytokines

173 on endothelial cell surfaces responsible for galectin-3-induced secretion of metastasis-promoting cyt

174 To elucidate the beneficial effects of galectin-3 inhibition on myocardial fibrogenesis, cultur

175 sing cell-based assays, indirectly linked to galectin-3 inhibition, showed no inhibition of galectin-

176 The efficacy of the galectin-3 inhibitor N-acetyllactosamine was evaluated i

177 r to that of a known nonselective galectin-1/galectin-3 inhibitor, which strongly suggests that block

178 ith galectin-3 in the absence or presence of galectin-3 inhibitor.

179 ollagen binding sites, such as revacept, and galectin-3 inhibitors in the prevention of colon cancer

180 sulted in highly selective and high affinity galectin-3 inhibitors.

181 ur results indicate that release of cellular galectin-3 into tears is associated with epithelial dysf

182 Galectin-3 is a beta-galactoside-binding lectin widely e

183 Galectin-3 is a biomarker associated with inflammation a

184 Galectin-3 is a family member of the carbohydrate-bindin

185 not expression of nectin-1, indicating that galectin-3 is a herpesvirus entry mediator.

186 Galectin-3 is a member of the galectin family that has a

187 for these proteases and that proteolysis of galectin-3 is a novel immune evasion mechanism.

188 These data indicate that galectin-3 is a regulatory component in melanin synthesi

189 bers present in synovial fluid, we find that galectin-3 is a specific, high-affinity binding partner

190 Galectin-3 is an active biomarker found in inflammatory

191 We find that galectin-3 is broadly up-regulated in KLF3-deficient mou

192 how expression of the inflammatory modulator galectin-3 is controlled, opening up avenues for potenti

193 The galactoside-binding protein galectin-3 is increasingly recognized as an important pl

194 enabling multivalency for various functions, galectin-3 is monomeric, and its functional multivalency

195 to initiate neutrophil migration even though galectin-3 is not a chemoattractant for neutrophils.

196 ts potential role as a prognostic biomarker, galectin-3 is not a critical modulator of cardiac fibros

197 The beta-galactoside-binding animal lectin galectin-3 is predominantly expressed by activated macro

198 Whether galectin-3 is related to LV remodeling after acute myoca

199 These results suggest that galectin-3 is strongly involved in Chagas disease, not o

200 The beta-galactoside-binding protein galectin-3 is widely expressed in well-differentiated th

201 Galectin-3 knock-out and wild-type mice were subjected t

202 Galectin-3 knock-out mice also developed LV hypertrophy

203 europrotection in the cortical region in the galectin-3 knockout animals in response to TBI.

204 Galectin-3 knockout mice exhibited accelerated cardiac h

205 7 days of pressure overload, whereas female galectin-3 knockouts had delayed dilation after 28 days

206 e decompensated HF, repeated measurements of galectin-3 level provided important and significant prog

207 zed by categorical and percentage changes in galectin-3 level.

208 mortality compared with stable or decreasing galectin-3 levels (hazard ratio in CORONA, 1.60; 95% con

209 The impact of changing galectin-3 levels on other secondary end points was comp

210 Increasing galectin-3 levels over time, from a low to high galectin

211 Galectin-3 levels were elevated in 22 patients (22%) at

212 Despite considerable interest in galectin-3, little is known about its physiological regu

213 t cardiomyocyte- but not macrophage-specific galectin-3 localization was associated with adverse remo

214 However, galectin-3 loss did not affect survival, systolic and di

215 ar surface, the carbohydrate-binding protein galectin-3 maintains barrier function by cross-linking t

216 2 (an interleukin-1 receptor family member), galectin-3, matrix metalloproteinase-2, and collagen III

217 We propose that galectin-3 may achieve multivalency through this multisi

218 suggest that following head trauma, released galectin-3 may act as an alarmin, binding, among other p

219 Drugs binding to galectin-3 may be potential therapeutic candidates for t

220 We hypothesized that galectin-3 may be up-regulated in the pressure-overloade

221 hat CD146/MCAM interactions with circulating galectin-3 may have an important influence on cancer pro

222 t clinical outcome in patients with AML, and galectin-3 may serve as a potential therapeutic target i

223 endothelial cell surface responsible for the galectin-3-mediated cytokine secretion.

224 In galectin-3(+/+) mice, SspB-expressing S. aureus caused l

225 acterial load or lesion size was detected in galectin-3(-/-) mice, which overall showed smaller lesio

226 tumorgenicity 2, highly sensitive troponin, galectin-3, midregional proadrenomedullin, cystatin-C, i

227 Serum galectin-3 modestly increased from baseline with canagli

228 anti-galectin-3 immunoprecipitation of free galectin-3 molecules not in a complex with U1 snRNP (fra

229 as biotinylated asialofetuin (biotin-ASF), a galectin-3 nanomolar binding partner, was bound to strep

230 initial parasite burden remained similar in galectin-3 null mice as compared with wild-type mice.

231 inding ligand and strongly co-localized with galectin-3 on endothelial cell surfaces treated with exo

232 Removal of galectin-3, one of basal-body components, provokes misre

233 ex and that U1 snRNP is required to assemble galectin-3 onto an active spliceosome.

234 alysis for candidate protein markers such as galectin-3, or analysis of differential microRNA express

235 th inhibitors of scavenger receptor class B, galectin-3, or blocking antibodies against CD36, suggest

236 tuent, however, increased the preference for galectin-3 over galectin-1 to more than 200-fold.

237 by baseline level of soluble form of ST2 and galectin 3; patients with values less than the observed

238 These studies define a galectin-3/phospho-caveolin-1/RhoA signaling module that

239 We conclude that galectin-3 plays a crucial role in the maintenance of th

240 Whether galectin-3 plays a pathological role in remodeling remai

241 y correlates with GFR in humans, but whether galectin-3 predicts incident kidney disease is unknown.

242 ds its cognate elements (CACCC boxes) in the galectin-3 promoter and represses its activation in cell

243 Remarkably, galectin-3 promotes cellular infiltration in the heart o

244 The concentration of galectin-3 protein in tears, but not galectin-3 expressi

245 quantitative Western blot, using recombinant galectin-3 protein to generate a calibration curve.

246 epithelial dysfunction in dry eye, and that galectin-3 proteolytic cleavage may contribute to impair

247 that association of transmembrane mucins to galectin-3 provides protection against viral infection.

248 In contrast, silencing galectin-3 reduced IL-8 response to LPG.

249 Galectin-3 regulates inflammasome activation in cholesta

250 Galectin-3 regulates inflammatory and fibrotic responses

251 Together, our results suggest that galectin-3 reinforces the lubricin boundary layer; which

252 However, the association among galectin-3, renal function, and adverse outcomes has not

253 Galectin-3 silencing inhibited the ARSB-silencing-induce

254 ats (VNTRs) that bind the lectin galectin-3; galectin-3 siRNA but not galectin-1 siRNA prevented MUC1

255 e B activity, with subsequent impact on C4S, galectin-3, Sp1, and Wnt9A and can exert significant eff

256 his study reviews several novel biomarkers - galectin-3, ST2 and copeptin.

257 ive hazard of adverse event than those whose galectin-3 stayed within +/-15% of the baseline value, i

258 In vitro, cytokine stimulation suppressed galectin-3 synthesis by macrophages and cardiac fibrobla

259 showed more arginine-arene interactions for galectin-3 than for galectin-1.

260 of antibody showed much higher affinity for galectin-3 than that of the commercial antibody.

261 ersican promoter activity increased, and the galectin-3 that co-immunoprecipitated with C4S declined.

262 ng galectin-3 but not in SKBR3 cells lacking galectin-3; the SKBR3 cells, however, can acquire the ab

263 The addition of galectin-3 to clinical predictors improved the C-statist

264 Considering the known ability of galectin-3 to crosslink glycoproteins, we hypothesized t

265 , these results indicate that HSV-1 exploits galectin-3 to enhance virus attachment to host cells and

266 er regulating this recycling, the binding of galectin-3 to particular glycoforms of transferrin.

267 rects cytosolic carbohydrate-binding protein Galectin-3 to PVs and that the delivery of GBP1 and GBP2

268 ppel-like factor 3 (KLF3) directly represses galectin-3 transcription.

269 V5-mediated Ca(2+) uptake was detected after galectin-3 treatment.

270 w document that this interaction between the galectin-3-U1 snRNP particle and the pre-mRNA results in

271 depleted extract can be reconstituted by the galectin-3-U1 snRNP particle, isolated by immunoprecipit

272 These results indicate that the galectin-3-U1 snRNP-pre-mRNA ternary complex is a functi

273 ve lepromatous form of leprosy; in contrast, galectin-3 was almost undetectable in self-limited tuber

274 Inhibition of galectin-3 was associated with a downregulation in colla

275 In dialysis patients, galectin-3 was associated with the combined end point of

276 His-tagged galectin-3 was bound to nickel chelate acceptor beads, w

277 In normal mouse myocardium, galectin-3 was constitutively expressed in macrophages a

278 Galectin-3 was highly expressed on macrophages in lesion

279 Galectin-3 was increased in TSC-related skin tumors, ang

280 Signature component Lgals3 encoding galectin-3 was increased in Tsc2-deficient cells and ser

281 Early up-regulation of galectin-3 was localized in subpopulations of macrophage

282 Plasma galectin-3 was measured at baseline and at 3 months in p

283 Galectin-3 was positively associated with remodeling in

284 When galectin-3 was silenced, the increases in Sp1 binding to

285 e activated, and secretion of the Mer ligand Galectin-3 was stimulated.

286 The cleavage of galectin-3 was studied in vitro using activated recombin

287 Higher plasma levels of galectin-3 were associated with rapid decline in eGFR (p

288 ng affinities to peanut agglutinin and human galectin-3 were measured by isothermal titration calorim

289 rms a lattice with the N-glycan of TRPV5 via galectin-3, which impairs TRPV5 endocytosis and increase

290 Galectin-3, which is highly expressed in HT29 cells, is

291 We have shown previously that circulating galectin-3, which is increased up to 30-fold in cancer p

292 We demonstrate that melanocytes express galectin-3, which is predominantly localized to the cell

293 The method employs a (89)Zr-labeled mAb to galectin-3, which shows high specificity and binding aff

294 erived from IGHV4-34 using PCNSL, recognized galectin-3, which was upregulated on microglia/macrophag

295 The association of galectin-3 with clinical end points was assessed by Cox

296 sion models to evaluate associations between galectin-3 with incident renal outcomes at examination 8

297 ic peptides, adrenomedullin, endothelin, and galectin-3 with new-onset HF was stronger in the high-ri

298 These data demonstrate an association of galectin-3 with unfavorable host response in leprosy and

299 is partly attributable to the interaction of galectin-3 with unknown receptor(s) on vascular endothel

300 iguingly, YopK limited the colocalization of Galectin-3 with YopD, suggesting that YopK limits the in